Innate CD8 T-cells as a potential predictive biomarker for deep molecular response in chronic myeloid leukemia patients

In chronic myeloid leukemia (CML), the role of immune effectors has been suggested in the achievement of a sustained deep molecular response (DMR) and treatment-free remission (TFR) after tyrosine kinase inhibitor (TKI) discontinuation. A contributory role of the distinct new innate CD8 T-cell pool in control of CML residual disease after TKI cessation was recently highlighted. Here, we evaluated longitudinally whether innate CD8 T-cells predict CML therapy success in a cohort of newly diagnosed CML patients treated in the DASA-PegIFN clinical trial. After 3 months of treatment (M3), we observed a significant increase in innate CD8 T-cell frequency as compared to diagnosis, together with an early shift within the pool of CD8 T-cells toward an innate/memory phenotype. We also found that patients with high innate CD8 T-cell frequency at M3 achieved DMR earlier and at higher rates than patients with low innate CD8 T-cell frequency. Remarkably, this signature pre-existed at the time of diagnosis, suggesting the possible role of the patient's initial individual immune status. High innate CD8 T-cell frequency was also associated with maintaining DMR stability for 2 years. Taken together, our findings highlight innate CD8 T-cells as a potential marker for CML therapy success and TFR eligibility.

Authors

Institutions

Publication Details

Journal
Cancer Immunology Immunotherapy
Published
2025-12-19
DOI
https://doi.org/10.1007/s00262-025-04256-0
Primary Topic
Chronic Myeloid Leukemia Treatments
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Innate CD8 T-cells as a potential predictive biomarker for deep molecular response in chronic myeloid leukemia patients

Jean‐Claude Chomel, Lydia Roy, Stéphanie Ragot, Amandine Decroos et al.
Cancer Immunology Immunotherapy
Chronic Myeloid Leukemia Treatments
article

Innate CD8 T-cells as a potential predictive biomarker for deep molecular response in chronic myeloid leukemia patients

Jean‐Claude Chomel, Lydia Roy, Stéphanie Ragot, Amandine Decroos, Florence Tartarin, Nathalie Piccirilli, Florence Jacomet, André Herbelin, Lucie Lefèvre, Alice Barbarin, François Guilhot, Franck E. Nicolini, Émilie Cayssials, Philippe Rousselot, Jean‐Marc Gombert
article en

Abstract

In chronic myeloid leukemia (CML), the role of immune effectors has been suggested in the achievement of a sustained deep molecular response (DMR) and treatment-free remission (TFR) after tyrosine kinase inhibitor (TKI) discontinuation. A contributory role of the distinct new innate CD8 T-cell pool in control of CML residual disease after TKI cessation was recently highlighted. Here, we evaluated longitudinally whether innate CD8 T-cells predict CML therapy success in a cohort of newly diagnosed CML patients treated in the DASA-PegIFN clinical trial. After 3 months of treatment (M3), we observed a significant increase in innate CD8 T-cell frequency as compared to diagnosis, together with an early shift within the pool of CD8 T-cells toward an innate/memory phenotype. We also found that patients with high innate CD8 T-cell frequency at M3 achieved DMR earlier and at higher rates than patients with low innate CD8 T-cell frequency. Remarkably, this signature pre-existed at the time of diagnosis, suggesting the possible role of the patient's initial individual immune status. High innate CD8 T-cell frequency was also associated with maintaining DMR stability for 2 years. Taken together, our findings highlight innate CD8 T-cells as a potential marker for CML therapy success and TFR eligibility.

Cancer Immunology ImmunotherapyVol. 75(1)
Inserm (FR), Université Paris-Est Créteil (FR), Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR), Université Paris-Saclay (FR), Centre Hospitalier Universitaire Henri-Mondor (FR), Université de Poitiers (FR), Centre Léon Bérard (FR), Centre Hospitalier Universitaire de Poitiers (FR), Centre de Recherche en Cancérologie de Lyon (FR), CEA Paris-Saclay (FR), Hôpitaux Universitaires Henri-Mondor (FR), Centre Hospitalier de Versailles (FR)
Centre Hospitalier Universitaire de Poitiers, Université de Poitiers, Defence and Security Accelerator
Openalex Percentile: Top 39%
Chronic Myeloid Leukemia Treatments
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.